300858 科拓生物
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)1.0635.4518.25011.53114.496
总资产报酬率 ROA (%)1.0245.1917.76010.73913.183
投入资产回报率 ROIC (%)1.0475.3618.08511.34414.451

边际利润分析
销售毛利率 (%)54.33754.58251.97550.31348.321
营业利润率 (%)37.65134.28734.55834.20134.707
息税前利润/营业总收入 (%)26.02426.26233.17532.33832.349
净利润/营业总收入 (%)31.37031.23929.76730.04228.475

收益指标分析
经营活动净收益/利润总额(%)83.49587.84889.41177.50794.004
价值变动净收益/利润总额(%)6.3647.2377.43310.5992.979
营业外收支净额/利润总额(%)0.012-0.549-1.529-0.427-4.007

偿债能力分析
流动比率 (X)21.46516.29615.56012.04611.907
速动比率 (X)20.61615.62714.96311.20011.212
资产负债率 (%)2.9804.2595.3087.0460.067
带息债务/全部投入资本 (%)0.4600.7370.9661.7150.113
股东权益/带息债务 (%)21,498.66113,323.43710,189.1205,668.95488,464.610
股东权益/负债合计 (%)3,255.3392,247.7411,783.7981,319.1931,399.050
利息保障倍数 (X)-2.237-3.350-38.431-18.825-31.703

营运能力分析
应收账款周转天数 (天)81.491101.453106.466115.992118.013
存货周转天数 (天)125.067119.403105.36796.95376.926